PER was not valued 200M$ which is what DXB was before failed trial. PER was 60M$ very cheap for drug in Ph2b with 20M$ cash. yes drug failed but there lot more indications ahead and i am still optimistic that jan results may reveal something interesting. happy to hold and wait given cash in hand, no CR for unforseable future and interesting news in Jan to see what company forward plans aee
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.87M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3790595 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 466666 | 3 |
View Market Depth
| Last trade - 10.04am 25/06/2025 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable